clinically relevant hemorrhage, and this hemorrhage was associated with a 5-times increased risk of death. [6] [7] [8] ICU-hospitalized dogs had a similar rate (7%) of clinically relevant hemorrhage associated with 5-fold increased risk of death; this included both dogs with melena (consistent with SRMD) and hematochezia, so the prevalence of SRMD cannot be extrapolated from this study. 9 Forty-nine percent of Alaskan sled dogs develop SRMD. 10 There are no models of the condition relevant to dogs.
In people, stress ulcer prophylaxis (SUP) has become the standard of care for prevention of SRMD in high-risk patient populations.
Human ICUs largely prescribe either proton pump inhibitors (PPIs, 66%
of SUP protocols) or histamine 2 receptor antagonists (H 2 RAs, 30% of SUP protocols). 11 Acid suppression with omeprazole leads to proliferation of bacteria in the gastric lumen in both species. 12, 13 PPI administration in people carries a 3.5-fold risk for the development of Clostridium difficile-associated diarrhea (CDAD), which is independently associated with longer ICU stays and increased mortality. 11, 14 The prevalence of infection by pathogenic Clostridia species in dogs receiving PPI treatment is unknown. Overall, a meta-analysis concluded that the evidence for SUP in human ICU patients is limited and further work is needed to determine the role of various SUP protocols on outcome. 15 A recent review of SRMD in dogs recommended standard use of SUP, particularly PPIs, in critically ill dogs. 16 Just as the efficacy of SUP for critically ill dogs has not been established, the adverse effects of acid suppression in critically ill dogs is unknown. There might be as yet unidentified risk factors for SRMD in dogs, as in people, that would be an indication for SUP.
Sucralfate, an alternative prophylactic treatment for SRMD, is a complex of sucrose and aluminum salts. Sucralfate binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone, allowing for epithelial restitution. 17 Sucralfate absorbs and reduces the activity of pepsin, and is cytoprotective as well as antiapoptotic. 18, 19 Sucralfate stimulates mucus synthesis and secretion and bicarbonate secretion. 20, 21 Compared with H 2 RAs and PPIs, this drug does not increase bacterial colonization and therefore has a lower likelihood of CDAD and is protective against the development of nosocomial pneumonia in people.
14 It was as effective as H 2 RAs for prevention of overt gastric bleeding events in critically ill people with lower rates of ventilator-associated pneumonia and gastric colonization. 22 Sucralfate does not affect CYP450 enzymes, so there is no effect on the therapeutic effect of concurrently administered medications. No SUP protocol has been examined for treatment or prevention of SRMD in dogs.
The objectives of this study were to develop an ex vivo SRMD model of canine gastric mucosa and to examine the effect of sucralfate on mucosal barrier function. Sucralfate was administered concurrently with acid injury and immediately after the injury with the aim of determining its efficacy both as a protective and reparative drug. The antral and pyloric regions of gastric mucosa were used as they are the most frequent sites for gastric ulceration in dogs. 
| Ussing chambers
Mucosa was bathed on both the mucosal and serosal sides of the tissue mounted on the chambers with 10 mL of oxygenated Ringer's solution maintained at 378C by water-jacketed reservoirs. As previously described, 24 10 mmol/L glucose was added to the serosal bathing solution, which was balanced with the addition of 10 mmol/L mannitol in the mucosal bathing solution. Treatments were applied to individual tissues after a 30-minute incubation period. Ringer's solution was titrated to pH 1.2 with hydrochloric acid. Sucralfate was dissolved in dimethyl sulfoxide (DMSO) at 1 g/mL as it was the maximum dose that was soluble; one milliliter was added to the 10-mL chamber to give a final dose of 100 mg/mL, or a total of 1 g.
DMSO was used as the recommended vehicle by the manufacturer.
One gram was selected as it is the recommended dose in vivo. 
| Stage 2: Sucralfate after acid injury
Acid injury was induced as previously described. Immediately after acid injury (75 minutes), 1 mL of 1 g/mL of sucralfate (sucrose octasulfate)
in DMSO was added to neutral Ringer's solution on the mucosal aspect of the tissue to give a final dose of 100 mg/mL. Controls included uninjured control, acid injury control, uninjured control 1 sucralfate, and injured control 1 vehicle (DMSO). Outcome measures were TER, 3 H-mannitol flux, and histological evaluation. These treatments were applied to mucosa from 8 dogs. Tissue from each dog was used in both treatment and control groups.
| Transepithelial resistance
The spontaneous potential difference (PD) was measured with Ringeragar bridges connected to calomel electrodes, and the PD was shortcircuited through silver-silver chloride electrodes with a voltage clamp that corrected for fluid resistance. TER (XÁcm 2 ) was calculated from the spontaneous PD and short circuit current (Isc). If the spontaneous PD was between 21 and 1 mV, tissues were current clamped at 6 100 lA for 5-seconds and the PD was recorded. The Isc and PD were recorded every 15 minutes for 210 minutes. Data were entered into spreadsheets that calculated TER from Isc and PD using Ohm's law.
| 3 H-mannitol flux
As a second indicator of gastric permeability, flux of 3 H-labeled mannitol across the mucosa was measured. Two-hundred molar of 3 H-radiolabeled mannitol was added to the mucosal reservoir. Samples were taken from both the serosal and mucosal reservoirs after 3 minutes to establish baseline radioactivity. As is standardly performed, 24 two 1-hour mucosalto-serosal fluxes were performed by sampling serosal bathing solutions at 1 and 2 hours after addition of radiolabeled mannitol.
| Histological examination
Gastric mucosal samples were taken for each dog before mounting on prostanoid and flux data. The Tukey's post hoc test was used to detect differences among treatments and time when significance was detected during the initial ANOVA. Histologic data was descriptively reported.
Significance was set at P < .05. Data are represented at means 6 SE. The effect of sucralfate on uninjured tissue was also examined.
Transepithelial resistance and mannitol flux were not different between control tissue and uninjured control with sucralfate added at 75 minutes (data not shown). In addition, DMSO, the vehicle for sucralfate delivery, was administered after acid injury; acid injury with the addition of DMSO showed similar TER recovery to acid-injured tissues in the absence of DMSO (data not shown).
Histologically, control tissues maintained largely unchanged morphology compared with baseline tissues taken at the time of tissue collection with only occasional apoptotic cells ( Figure 5A,B) . However, exposure to HCl induced moderate to marked sloughing of the superficial gastric epithelium with associated thickening of the mucus layer ( Figure 5C ). When sucralfate was administered concurrently with acid, little to no tissue sloughing or apoptosis was noted in any samples although the mucus/sucralfate layer was of a similar thickness to the acid-injured control tissue ( Figure 5D ).
| Stage 2: Sucralfate after acid injury: Sucralfate enhances recovery when administered after acid injury
To evaluate sucralfate as a treatment for pre-existing alterations in barrier function, sucralfate was applied after the initial acid injury in gastric tissues from n 5 8 dogs. The acid injury was applied as described previously. Immediately after acid injury (at the completion of the 45-minute injury period), sucralfate was applied to the mucosal bathing reservoir to give a concentration of 100 mg/mL in neutral Ringer's solution. In 
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